Arvinas, Inc. (ARVN)
Market Cap | 488.31M |
Revenue (ttm) | 426.90M |
Net Income (ttm) | -46.60M |
Shares Out | 72.99M |
EPS (ttm) | -0.65 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,891,353 |
Open | 6.60 |
Previous Close | 6.51 |
Day's Range | 6.48 - 6.79 |
52-Week Range | 5.90 - 36.20 |
Beta | 2.23 |
Analysts | Buy |
Price Target | 21.13 (+215.85%) |
Earnings Date | May 1, 2025 |
About ARVN
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration... [Read more]
Financial Performance
In 2024, Arvinas's revenue was $263.40 million, an increase of 235.54% compared to the previous year's $78.50 million. Losses were -$198.90 million, -45.85% less than in 2023.
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for ARVN stock is "Buy." The 12-month stock price forecast is $21.13, which is an increase of 215.85% from the latest price.
News

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Shareholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN)...

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Shareholders to Connect
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN)...

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Shareholders to Reach Out
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN)...

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Shareholders to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN)...

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Investors to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN)...

Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / May 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN)...

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Investors to Connect
NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN)....

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Stockholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN)....

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Investors to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN)....

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Investors to Reach Out
NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN)....

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Stockholders to Reach Out
NEW YORK, NY / ACCESS Newswire / May 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN)....

Arvinas: Yet Another Biotech Trading Below Net Cash, But It's Only A Mild Bull Case
I favor biotech stocks trading below cash value after setbacks; Arvinas (ARVN) fits this description, dropping 25% on Thursday after ending two Phase 3 trials. ARVN's net cash per share is over $12, p...

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Stockholders to Connect
NEW YORK, NY / ACCESS Newswire / May 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN)....

Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / May 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN)....

Arvinas, Inc. (ARVN) Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation
BOSTON, MA / ACCESS Newswire / May 2, 2025 / Block & Leviton is investigating Arvinas, Inc. (Nasdaq:ARVN) for potential securities law violations. Investors who have lost money in their Arvinas, Inc. ...

Arvinas, Inc. (ARVN) Q1 2025 Earnings Call Transcript
Arvinas, Inc. (NASDAQ:ARVN) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Jeff Boyle - Vice President of Investor Relations John Houston - President and Chief Executive...

Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update
– Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first-in-human data for the Company's first neuroscience program with ARV-102 ...

Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation,...

Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting
– ARV-393 demonstrated strong synergistic antitumor activity, including complete regressions, in combination with standard-of-care chemotherapy, biologics, and select investigational oral small molecu...

Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
– Oral presentation will serve as first presentation of detailed results from the Phase 3 VERITAC-2 clinical trial –

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting
Company to highlight preclinical study of ARV-393, an investigational PROTAC BCL6 degrader, in combination with standard of care therapies Company to highlight preclinical study of ARV-393, an investi...

Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study
Arvinas, Inc. ARVN unveiled first-in-human data on Friday for its experimental Parkinson's disease treatment, ARV-102.

Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation
– Data demonstrate that ARV-102 was well tolerated, orally bioavailable, and brain-penetrant; ARV-102 achieved central and peripheral LRRK2 reduction indicating substantial LRRK2 protein degradation i...

Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer's & Parkinson's Diseases
– Company to highlight first-in-human data from healthy volunteers in both the single-ascending and multiple-ascending dose portions of a Phase 1 study of ARV-102, an investigational PROTAC LRRK2 degr...

Top 3 Health Care Stocks That Are Set To Fly This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.